{
    "clinical_study": {
        "@rank": "82163", 
        "arm_group": [
            {
                "arm_group_label": "study arm", 
                "arm_group_type": "Experimental", 
                "description": "For patients who are randomized to study arm, (i.e. to irradiate the post-chemotherapy tumor extent) the clinical target volume-tumor (CTV-T) includes the post-chemotherapy gross tumor volume-tumor (GTV-T) with a margin of 0.8 cm.\nChemotherapy includes etoposide 100mg/m2 d1-d3 combine with cisplatin 80mg/m2 d1 at 21-day interval for 4 cycles.\nRadiotherapy will be administered with cycle 3 chemotherapy\uff081.5 Gy twice daily to 45 Gy in 30 fractions over 3 weeks\uff09"
            }, 
            {
                "arm_group_label": "control arm", 
                "arm_group_type": "Active Comparator", 
                "description": "For patients who are randomized to control arm, (i.e. to irradiate the pre-chemotherapy tumor extent) the clinical target volume-tumor (CTV-T) includes the pre-chemotherapy gross tumor volume-tumor (GTV-T) with a margin of 0.8 cm.\nChemotherapy includes etoposide 100mg/m2 d1-d3 combine with cisplatin 80mg/m2 d1 at 21-day interval for 4 cycles.\nRadiotherapy will be administered with cycle 3 chemotherapy (1.5 Gy twice daily to 45 Gy in 30 fractions over 3 weeks)."
            }
        ], 
        "brief_summary": {
            "textblock": "We hypothesized that the local control for both arms were not statistically significant,\n      when irradiation to the post-induction chemotherapy tumor volume is compared with\n      irradiation to the pre-induction chemotherapy tumor volume.While elective nodal irradiation\n      will be omitted for both arms."
        }, 
        "brief_title": "A Prospective Randomized Study Comparing the Target Volume for Limited-stage Small Cell Lung Cancer", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Carcinoma of Lung", 
            "Small Cell", 
            "Limited Stage"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Lung Neoplasms", 
                "Small Cell Lung Carcinoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients were eligible if they had histologic or cytologic verification of small cell\n             lung cancer (SCLC) and were radiographically confirmed limited-stage\n\n          -  Patients with contralateral mediastinal and ipsilateral supraclavicular\n             lymphadenopathy were also included.\n\n          -  The patients should be between 18 and 75 years old without previous thoracic\n             radiotherapy, chemotherapy or biotherapy.\n\n          -  Karnofsky performance status was \u2265 80.\n\n          -  Forced expiratory volume at 1 second (FEV1) \u2265 1 L.\n\n          -  Had measurable or assessable disease.\n\n          -  Neutrophilic granulocyte \u2265 1.5\u00d7109/L, haemoglobin \u2265 100 g/L, platelet count \u2265\n             100\u00d7109/L.\n\n          -  Serum creatine and bilirubin < 1.5 \u00d7 the upper normal limit (UNL), aminotransferase <\n             2 \u00d7 UNL.\n\n          -  Weight loss was less than 10% within 6 months before diagnosis.\n\n          -  Written informed consent was required from all patients.\n\n        Exclusion Criteria:\n\n          -  Patients were ineligible if they had a history of other malignant diseases except for\n             non-melanomatous skin cancer and carcinoma in situ of the cervix, or any\n             contraindications for chemoradiotherapy, malignant pleural and/or pericardial\n             effusion."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01731548", 
            "org_study_id": "2012-10-25"
        }, 
        "intervention": {
            "arm_group_label": [
                "study arm", 
                "control arm"
            ], 
            "description": "1.5 Gy twice daily to 45 Gy in 30 fractions over 3 weeks for both arms", 
            "intervention_name": "hyperfractionated radiation therapy for both arms", 
            "intervention_type": "Radiation"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 21, 2013", 
        "location": {
            "contact": {
                "email": "liuhui@sysucc.org.cn", 
                "last_name": "Hui Liu, MD. PHD", 
                "phone": "086-020-87343033"
            }, 
            "contact_backup": {
                "email": "baoyong@sysucc.org.cn", 
                "last_name": "Yong Bao, MD", 
                "phone": "086-020-87343504"
            }, 
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510060"
                }, 
                "name": "Sun Yat-Sen University, Cancer Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Omitting Elective Nodal Irradiation and Irradiating Post-induction Versus Pre-induction Chemotherapy Tumor Extent for Limited-stage Small Cell Lung Cancer", 
        "overall_contact": {
            "email": "gzcm@263.net", 
            "last_name": "Ming Chen, MD", 
            "phone": "+86 18758875572"
        }, 
        "overall_official": {
            "affiliation": "Zhejiang Cancer Hospital", 
            "last_name": "Ming Chen, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "local-regional progression", 
            "safety_issue": "Yes", 
            "time_frame": "at least 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01731548"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "overall survival", 
            "safety_issue": "Yes", 
            "time_frame": "at least 1 year"
        }, 
        "source": "Zhejiang Cancer Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Sun Yat-sen University", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Zhejiang Cancer Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2002", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}